Regeneron Pharmaceuticals, Inc.
Stabilized Formulations Containing Anti-CTLA-4 Antibodies

Abstract:

The present invention provides liquid and lyophilized pharmaceutical formulations comprising an antibody that specifically binds to human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4). The formulations may contain, in addition to an anti-CTLA-4 antibody, a buffer, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.